Checkpoint Therapeutics Announces Initiation of CONTERNO Phase III Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line Non-squamous Non-Small Cell Lung Cancer

Checkpoint Therapeutics, Inc. announced the initiation of the CONTERNO study, a global, randomized Phase III trial of cosibelimab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with non-squamous non-small cell lung cancer.